| DIRECT COMPETITOR COMPARISON | |
| ELI | KG | MYL | Pvt1 | Industry | | Market Cap: | N/A | 3.01B | 5.73B | N/A | N/A | | Employees: | N/A | 3,381 | 15,000 | 1501 | N/A | | Qtrly Rev Growth (yoy): | N/A | 19.30% | -23.70% | N/A | N/A | | Revenue (ttm): | N/A | 1.69B | 4.92B | 200.00K1 | N/A | | Gross Margin (ttm): | N/A | 68.58% | 40.52% | N/A | N/A | | EBITDA (ttm): | N/A | 533.79M | 1.06B | N/A | N/A | | Oper Margins (ttm): | N/A | 21.23% | 13.54% | N/A | N/A | | Net Income (ttm): | N/A | -472.15M | 49.70M | N/A | N/A | | EPS (ttm): | N/A | -1.933 | 0.163 | N/A | N/A | | P/E (ttm): | N/A | N/A | 114.97 | N/A | N/A | | PEG (5 yr expected): | N/A | 1.61 | 0.78 | N/A | N/A | | P/S (ttm): | N/A | 1.80 | 1.16 | N/A | N/A |
|
| NEWS ON DIRECT COMPETITORS | |
| | MYL | | Many Reasons to Launch a Global Generic Drug ETF Thu, Dec 24 -
at Seeking Alpha | | | MYL | | Vytorin Update: Cancer Risk, Generic Challenge Tue, Dec 22 -
at The Wall Street Journal Online | | | MYL | | Big Pharmas Love-Hate With India Tue, Dec 22 -
at Minyanville.com | | | MYL | | Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets Tue, Dec 22 -
PR Newswire | | | MYL | | UPDATE - Mylan seeks approval of generic of Merck's Vytorin Tue, Dec 22 -
at Reuters | | | MYL | | Mylan sued over plans for generic Vytorin Tue, Dec 22 -
AP | | | MYL | | Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication Tue, Dec 22 -
PR Newswire | | | KG | | Stealth Generic Drug Play: 1 Minute Trade Mon, Dec 14 -
TheStreet.com TV | | | KG | | [video] Stealth Generic Drug Play: 1 Minute Trade Fri, Dec 11 -
at TheStreet.com | | | KG | | ZymoGenetics claims court win versus King Thu, Dec 10 -
at bizjournals.com | | | KG | | UPDATE - Zymogenetics says court denies King Pharma motion Thu, Dec 10 -
at Reuters | | | KG | | KING PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Wed, Dec 9 -
EDGAR Online | | | All Headlines for these symbols... |
|
|
|